Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00973427
Official study title

DNA Chip Based Prognosis of Lung Cancer

Study summary

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 23, 2015 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?5 U.S. locations

Locations may change over time.

Who runs it?Medical Prognosis Institute A/S

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Medical Prognosis Institute A/S
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. A histological diagnosis of primary NSCLC stage Ia 2. Surgical removal of the tumor 3. Age between 18 and 75 years 4. Ability to understand and the willingness to sign a written informed consent document.

Reasons someone may not be able to joinExclusion criteria

1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery. 2. Adjuvant treatment with chemotherapy. 3. Prior history of cancer in the past 5 years or breast cancer at any time. 4. Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of AlabamaBirmingham, Alabama
  • Roswell Park Cancer InstituteBuffalo, New York
  • Aarhus University HospitalAarhus
  • University of CopenhagenCopenhagen
  • Odense University HospitalOdense

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 23, 2015. Always confirm current availability with the study team.

View original record ↗